IGF1 Genotype and Breast Cancer Risk
Author Information
Author(s): DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, Stanczyk F, Probst-Hensch N M
Primary Institution: University of Southern California, Norris Comprehensive Cancer Center
Hypothesis
The (CA)19 homozygous genotype (19/19) might indicate women with a decreased lifetime exposure to IGF1 and consequently, a decreased susceptibility to breast cancer.
Conclusion
The study found that circulating IGF1 levels in postmenopausal women differed significantly between Latino-American women and three other racial/ethnic groups, but the IGF1 (CA)19 genotype was not a relevant genetic marker for breast cancer risk.
Supporting Evidence
- Latino-American women had the lowest mean plasma IGF1 levels among the four racial/ethnic groups.
- The 19/19 genotype was not predictive of low breast cancer risk in the study population.
- Mean plasma IGF1 concentrations differed significantly between racial/ethnic groups.
Takeaway
This study looked at how a gene related to IGF1 might affect breast cancer risk in women from different backgrounds, but it didn't find a clear link.
Methodology
The study involved a nested case-control design with 800 postmenopausal women from four racial/ethnic groups, examining plasma IGF1 levels and genotyping for the IGF1 (CA)n microsatellite variant.
Potential Biases
There was potential for random misclassification in genotype determination.
Limitations
The study had small sample sizes in some racial/ethnic strata, which may have reduced statistical power.
Participant Demographics
Participants included 800 postmenopausal women from African American, Japanese American, Latino American, and Non-Latino White backgrounds.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI 0.30–2.24
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website